Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials

Chest
Jonathan A RoseAdriano R Tonelli

Abstract

In recent years, the population of patients with pulmonary arterial hypertension (PAH) has changed dramatically, including more advanced age at diagnosis. We hypothesized that older patients have a distinct clinical profile with different disease characteristics and response to intervention. All previously published treatment studies for PAH conducted by United Therapeutics including seven randomized, placebo-controlled trials and one extension study were included and analyzed to assess the association of age with various demographic, functional, hemodynamic, and outcome variables. A total of 2,627 patients across three age groups were included: ≤ 50 (n = 1,438, 54.7%), 51 to 64 (n = 780, 29.7%), and ≥ 65 years (n = 409, 15.6%). In comparison with the youngest group, the oldest age group had higher proportions of connective tissue disease-associated etiology (range across the studies, 27%-49% vs 13%-21%), higher proportions of New York Heart Association Functional classes III and IV (74%-91% vs 57%-84%), shorter baseline 6-min walk distance (6MWD) (261-316 vs 335-371 m), better hemodynamic measurements including lower baseline mean pulmonary artery pressure (48-51 vs 58-63 mmHg), and smaller changes in 6MWD from baseline to end...Continue Reading

References

Nov 17, 1998·American Journal of Respiratory and Critical Care Medicine·P L Enright, D L Sherrill
Oct 19, 2005·Respiratory Medicine·Bernadine CamarriSue Jenkins
Sep 22, 2006·Rheumatology·C M Kähler, D Colleselli
Jan 16, 2007·Chest·Brian P ShapiroMargaret M Redfield
Dec 22, 2009·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Jagdish HiremathUNKNOWN TRUST Study Group
May 1, 2010·Journal of the American College of Cardiology·Vallerie V McLaughlinWerner Seeger
Dec 14, 2011·Journal of Science and Medicine in Sport·Marcos G SantanaMarco T de Mello
Mar 2, 2012·European Respiratory Review : an Official Journal of the European Respiratory Society·M D McGoon, D P Miller
Nov 21, 2012·International Journal of Cardiology·Marius M HoeperDavid Pittrow
Apr 23, 2013·American Journal of Respiratory and Critical Care Medicine·Adriano R TonelliRaed A Dweik
Oct 29, 2013·Current Hypertension Reports·Dan-Chen WuZhi-Cheng Jing
Dec 21, 2013·Journal of the American College of Cardiology·Marius M HoeperDavid B Badesch
Dec 21, 2013·Journal of the American College of Cardiology·Michael D McGoonMarc Humbert
Feb 1, 2014·Chest·Meredith E PughAnna R Hemnes
Feb 4, 2014·American Journal of Respiratory and Critical Care Medicine·Raed A DweikUNKNOWN ATS Committee on Pulmonary Hypertension Phenotypes
Aug 15, 2014·Chest·Stephen C MathaiRobert A Wise
Mar 21, 2015·Heart, Lung & Circulation·Sreekanth KodurNicholas Collins

❮ Previous
Next ❯

Citations

Jun 10, 2017·Pulmonary Circulation·Kishan S ParikhSudarshan Rajagopal
Aug 21, 2018·Pulmonary Circulation·Marylise GinouxSégolène Turquier
Apr 7, 2018·The European Respiratory Journal·Clara HjalmarssonUNKNOWN SveFPH and SPAHR
Jan 22, 2021·Expert Review of Respiratory Medicine·Pilar Escribano SubíasMaria Francesca Perelló
Jan 16, 2021·The European Respiratory Journal·Laurent SavaleChristophe Guignabert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.